Logotipo del repositorio
Logotipo del repositorio
 

Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorRosende, Andres
dc.contributor.authorRomero, Cesar
dc.contributor.authorDiPette, Donald
dc.contributor.authorBrettler, Jeffrey
dc.contributor.authorVan der Stuyft, Patrick
dc.contributor.authorSatheesh, Gautam
dc.contributor.authorPerel, Pablo
dc.contributor.authorChapman, Niamh
dc.contributor.authorMoran, Andrew
dc.contributor.authorSchutte, Aletta
dc.contributor.authorSharman, James
dc.contributor.authorIRAZOLA, VILMA
dc.contributor.authorHuffman, Mark
dc.contributor.authorCampbell, Norm
dc.contributor.authorAbdul Salam, Mohammad
dc.contributor.authorLanas, Fernando
dc.contributor.authorCoca, Antonio
dc.contributor.authorGarcia-Zamora, Sebastian
dc.contributor.authorFERREIRO, ALEJANDRO
dc.contributor.authorLopez-Jaramillo, Patricio
dc.contributor.authorRico-Fontalvo, Jorge
dc.contributor.authorRidley, Emily
dc.contributor.authorPicone, Dean
dc.contributor.authorFlood, David
dc.contributor.authorPiñeiro, Daniel José
dc.contributor.authorNeira Ojeda, Carolina
dc.contributor.authorRodriguez, Gonzalo
dc.contributor.authorWellmann, Irmgardt A.
dc.contributor.authorOrias, Marcelo
dc.contributor.authorRivera, Marcela
dc.contributor.authorVillatoro, Matías
dc.contributor.authorOnuma, Oyere
dc.contributor.authorRAMROOP, SHAUN
dc.contributor.authorKhan, Taskeen
dc.contributor.authorValdés González, Yamilé
dc.contributor.authorSebba Barroso Souza, Weimar Kunz
dc.contributor.authorPlavnik, Frida
dc.contributor.authorZúñiga, Eric
dc.contributor.authorGrassani, Ana María
dc.contributor.authorTajer, Carlos
dc.contributor.authorZaidel, Ezequiel J
dc.contributor.authorMARIN, MARCOS
dc.contributor.authorCyr Philbert, Shana
dc.contributor.authoramorin, ignacio
dc.contributor.authorDiaz-Aguilera, Miguel Angel
dc.contributor.authorBortolotto, Luiz
dc.contributor.authorAVEZUM, ALVARO
dc.contributor.authorRibeiro, Antonio
dc.contributor.authorTobe, Sheldon
dc.contributor.authorAumala Viscarra, Teresa Natalia
dc.contributor.authorAngell, Sonia
dc.contributor.authorLavados, Pablo
dc.contributor.authorMartins, Sheila
dc.contributor.authorMunera, Ana
dc.contributor.authorJaffe, Marc
dc.contributor.authorPrabhakaran, Dorairaj
dc.contributor.authorParati, Gianfranco
dc.contributor.authorZhang, Xin-Hua
dc.contributor.authorRodgers, Anthony
dc.contributor.authorYusuf, Salim
dc.contributor.authorWhelton, Paul
dc.contributor.authorOrdunez, Pedro
dc.date.accessioned2025-05-28T13:13:22Z
dc.date.available2025-05-28T13:13:22Z
dc.date.issued2025
dc.description.abstractBackground: HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative, aimed at helping countries enhance hypertension and cardiovascular disease (CVD) risk management in primary care settings. Its core implementation tool, the HEARTS Clinical Pathway, has been adopted by 28 countries. To improve the care of hypertension, diabetes, and chronic kidney disease (CKD), HEARTS 2.0 was developed as a three-phase process to integrate evidence-based interventions into a unified care pathway, ensuring consistency across fragmented guidelines. This paper focuses on Phase 1, highlighting targeted interventions to improve and update the HEARTS Clinical Pathway. Methods: First, the coordinating group defined the project’s scope, objectives, principles, methodological framework, and tools. Second, international experts from different disciplines proposed interventions to enhance the HEARTS Clinical Pathway. Third, the coordinating group harmonized these proposals into unique interventions. Fourth, experts appraised the appropriateness of the proposed interventions on a 1-to 9 scale using the adapted RAND/UCLA Appropriateness Method. Finally, interventions with a median score above 6 were deemed appropriate and selected as candidates to enhance the HEARTS Clinical Pathway. Results: Building on the existing HEARTS Clinical Pathway, 45 unique interventions were selected, including community-based screening, early detection and management of risk factors, lower blood pressure thresholds for diagnosing hypertension in high CVD-risk patients, reinforcement of single-pill combination therapy, inclusion of sodium-glucose cotransporter-2 inhibitors for patients with diabetes, CKD, or heart failure, expanded roles for non-physician health workers in team-based care, and strengthened clinical documentation, monitoring, and evaluation.eng
dc.format.mimetypepdf
dc.identifier.citationRosende A, Romero C, DiPette DJ, Brettler J, Van der Stuyft P, Satheesh G, Perel P, Chapman N, Moran AE, Schutte AE, Sharman JE, Irazola V, Huffman MD, Campbell NRC, Salam A, Lanas F, Coca A, Garcia-Zamora S, Ferreiro A, Lopez-Jaramillo P, Rico-Fontalvo J, Ridley E, Picone D, Flood D, Piñeiro DJ, Ojeda CN, Rodriguez G, Wellmann IA, Orias M, Rivera M, Reyes MV, Onuma O, Ramroop S, Khan T, Gonzalez YV, Barroso WKS, Plavnik FL, Zuniga E, Grassani AM, Tajer C, Zaidel E, Marin MJ, Cyr-Philbert S, Amorin I, Diaz Aguilera MA, Bortolotto L, Avezum A, Ribeiro ALP, Tobe S, Aumala T, Angell S, Lavados P, Martins SO, Echeverri AM, Jaffe MG, Prabhakaran D,Parati G, Zhang XH, Rodgers A, Yusuf S, Whelton PK, Ordunez P. Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1. Global Heart. 2025; 20(1): 45. DOI: https://doi.org/10.5334/gh.1428
dc.identifier.doihttps://doi.org/10.5334/gh.1428
dc.identifier.issn22118179 (Electrónico)
dc.identifier.issn22118160 (Impreso)
dc.identifier.urihttps://hdl.handle.net/20.500.12442/16630
dc.identifier.urlhttps://globalheartjournal.com/articles/1428/files/683599615fc84.pdf
dc.language.isoeng
dc.publisherUbiquity Presseng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationaleng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceGlobal Hearteng
dc.sourceVol.  20 No. 1, (2025)spa
dc.subject.keywordsHypertensioneng
dc.subject.keywordsPrimary Health Careeng
dc.subject.keywordsCardiovascular Diseaseseng
dc.subject.keywordsDiabetes mellituseng
dc.subject.keywordsRenal Insufficiencyeng
dc.subject.keywordsChroniceng
dc.subject.keywordsStrokeeng
dc.titleCandidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1eng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científico
dcterms.referencesKhan T, Moran AE, Perel P, Whelton PK, Brainin M, Feigin V, et al. The HEARTS partner forum supporting implementation of HEARTS to treat and control hypertension. Front Public Health. 2023;24(11):1146441. DOI: https://doi.org/10.3389/fpubh.2023.1146441eng
dcterms.referencesOrdunez P, Campbell NRC, DiPette DJ, Jaffe MG, Rosende A, Martinez R, et al. HEARTS in the Americas: Targeting health system change to improve population hypertension control. Curr Hypertens Rep. 2024;26(4):141–156. DOI: https://doi.org/10.1007/s11906-023-01286-weng
dcterms.referencesMoran AE, Gupta R, Global Hearts Initiative Collaborators. Implementation of Global Hearts Hypertension Control Programs in 32 low- and middle-income countries: JACC International. J Am Coll Cardiol. 2023;82(19):1868–1884. DOI: https://doi.org/10.1016/j.jacc.2023.08.043eng
dcterms.referencesMartinez R, Soliz P, Campbell NRC, Lackland DT, Whelton PK, Ordunez P. Association between population hypertension control and ischemic heart disease and stroke mortality in 36 countries of the Americas, 1990–2019: An ecological study. Rev Panam Salud Publica. 2022;46:e143. DOI: https:// doi.org/10.26633/RPSP.2022.143eng
dcterms.referencesRosende A, DiPette D, Brettler J, Rodríguez G, Zuniga E, Connell K, et al. HEARTS in the Americas appraisal checklist and clinical pathway for comprehensive hypertension management in primary care. Rev Panam Salud Publica. 2022;2(46):e125. DOI: https://doi.org/10.26633/RPSP.2022.125eng
dcterms.referencesCampbell NRC, Paccot Burnens M, Whelton PK, Angell SY, Jaffe MG, Cohn J, et al. 2021 World Health Organization guideline on pharmacological treatment of hypertension: Policy implications for the region of the Americas. Lancet Reg Health Am. 2022;9. DOI: https://doi.org/10.1016/j. lana.2022.100219eng
dcterms.referencesBrettler JW, Arcila GPG, Aumala T, Best A, Campbell NR, Cyr S, et al. Drivers and scorecards to improve hypertension control in primary care practice: Recommendations from the HEARTS in the Americas Innovation Group. Lancet Reg Health Am. 2022 May;9. DOI: https://doi.org/10.1016/j. lana.2022.100223eng
dcterms.referencesDiPette DJ, Goughnour K, Zuniga E, Skeete J, Ridley E, Angell S, et al. Standardized treatment to improve hypertension control in primary health care: the HEARTS in the Americas initiative. J Clin Hypertens. 2020;22(12):2285–2295. DOI: https://doi.org/10.1111/jch.14072eng
dcterms.referencesDiPette DJ, Skeete J, Ridley E, Campbell NRC, Lopez-Jaramillo P, Kishore SP, et al. Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. J Clin Hypertens (Greenwich). 2019;21(1):4–15. DOI: https://doi.org/10.1111/ jch.13426eng
dcterms.referencesOrdunez P, Tajer C, Gaziano T, Rodriguez YA, Rosende A, Jaffe MG. The HEARTS app: A clinical tool for cardiovascular risk and hypertension management in primary health care. Rev Panam Salud Publica. 2022;28(46):e12. DOI: https://doi.org/10.26633/RPSP.2022.12eng
dcterms.referencesRosende A, DiPette DJ, Martinez R, Brettler JW, Rodriguez G, Zuniga E, et al. HEARTS in the Americas clinical pathway. Strengthening the decision support system to improve hypertension and cardiovascular disease risk management in primary care settings. Front Cardiovasc Med. 2023;10:1102482. DOI: https://doi.org/10.3389/fcvm.2023.1102482eng
dcterms.referencesOrdunez P, Lombardi C, Picone DS, Brady TM, Campbell NRC, Moran AE, et al. HEARTS in the Americas: A global example of using clinically validated automated blood pressure devices in cardiovascular disease prevention and management in primary health care settings. J Hum Hypertens. 2023;37(2):126–129. DOI: https://doi.org/10.1038/s41371-022-00659-zeng
dcterms.referencesRangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. on behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation. 2019;139:e840–e878. DOI: https://doi.org/10.1161/CIR.0000000000000664eng
dcterms.referencesNdumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. American Heart Association. A synopsis of the evidence for the science and clinical management of cardiovascular kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation. 2023;148(20):1636–1664. DOI: https://doi.org/10.1161/CIR.0000000000001186eng
dcterms.referencesPAHO. Better Care for NCDs: Accelerating Actions in Primary Health Care. [Internet]. Available at: https://www.paho.org/en/documents/better-care-ncds-accelerating-actions-primary-health-care. (Access: 12 – Nov – 2024).eng
dcterms.referencesBrook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986;2(1):53–63. DOI: https://doi.org/10.1017/S0266462300002774eng
dcterms.referencesSatheesh G, Dhurjati R, Huffman MD, Rosende A, Rodgers A, Prabhakaran D, et. Al. Standardized treatment protocols for hypertension: Global availability, characteristics, and alignment with the hypertension guideline recommendations. J Hypertens. 2024;42(5):902–908. DOI: https://doi. org/10.1097/HJH.0000000000003636eng
dcterms.referencesOrdunez P, Campbell NRC, Giraldo Arcila GP, Angell SY, Lombardi C, Brettler JW, et al. HEARTS in the Americas: Innovations for improving hypertension and cardiovascular disease risk management in primary care. Rev Panam Salud Publica. 2022;46:e96. PMID: 35855441; PMCID: PMC9288223. DOI: https://doi.org/10.26633/RPSP.2022.96eng
dcterms.referencesCheung AK, Whelton PK, Muntner P, Schutte AE, Moran AE, Williams B, et al. International consensus on standardized clinic blood pressure measurement – a call to action. Am J Med. 2023;136(5):438–445.e1. DOI: https://doi.org/10.1016/j.amjmed.2022.12.015eng
dcterms.referencesSharman JE, Ordunez P, Brady T, Parati G, Stergiou G, Whelton PK, et al. The urgency to regulate validation of automated blood pressure measuring devices: a policy statement and call to action from the world hypertension league. J Hum Hypertens. 2023;37(2):155–159. DOI: https://doi. org/10.1038/s41371-022-00747-0eng
dcterms.referencesWhelton PK, Picone DS, Padwal R, Campbell NRC, Drawz P, Rakotz MK, et al. Global proliferation and clinical consequences of non-validated automated BP devices. J Hum Hypertens. 2023;37(2):115–119. DOI: https://doi.org/10.1038/s41371-022-00667-zeng
dcterms.referencesPicone DS, Campbell NRC, Schutte AE, Olsen MH, Ordunez P, Whelton PK, et al. Validation status of blood pressure measuring devices sold globally. JAMA. 2022;327(7):680–681. DOI: https://doi. org/10.1001/jama.2021.24464eng
dcterms.referencesLombardi C, Picone DS, Sharman JE, Campbell NRC, Farias R, Guerre S, et al. Country experiences on the path to exclusive use of validated automated blood pressure measuring devices within the HEARTS in the Americas Initiative. J Hum Hypertens. 2023;37(2):120–125. Epub 2022 Jul 11. PMID: 35817799; PMCID: PMC9957722. DOI: https://doi.org/10.1038/s41371-022-00706-9eng
dcterms.referencesWhelton PK, O’Connell S, Mills KT, He J. Optimal antihypertensive systolic blood pressure: A systematic review and meta-analysis. Hypertension. 2024;81(11):2329–2339. DOI: https://doi. org/10.1161/HYPERTENSIONAHA.124.23597eng
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314. DOI: https://doi.org/10.1016/j.kint.2023.10.018eng
dcterms.referencesWorld Health Organization (September 19, 2023). Global report on hypertension: the race against a silent killer. [Internet]. Available at: https://www.who.int/publications/i/item/9789240081062eng
dcterms.referencesGBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–234. DOI: https://doi.org/10.1016/S0140- 6736(23)01301-6. Epub 2023 Jun 22. Erratum in: Lancet. 2023 Sep 30;402(10408):1132. DOI: https://doi.org/10.1016/S0140-6736(23)02044-5eng
dcterms.referencesNCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: A pooled analysis of 1101 population-representative studies with 82 million participants. Lancet. 2024;S0140-6736(24)02317-1. DOI: https://doi.org/10.1016/S0140- 6736(24)02317-1eng
dcterms.referencesLiu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. ESPRIT Collaborative Group. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245–255. DOI: https://doi.org/10.1016/S0140-6736(24)01028-6eng
dcterms.referencesCheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):559–569. DOI: https://doi.org/10.1016/j.kint.2020.10.026eng
dcterms.referencesJin Y, Wang K, Xiao B, Wang M, Gao X, Zhang J, et al. Global burden of atrial fibrillation/flutter due to high systolic blood pressure from 1990 to 2019: Estimates from the global burden of disease study 2019. J Clin Hypertens (Greenwich). 2022;24(11):1461–1472. DOI: https://doi.org/10.1111/jch.14584eng
dcterms.referencesDong XJ, Wang BB, Hou FF, Jiao Y, Li HW, Lv SP, et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2019. Europace. 2023;25(3):793–803. DOI: https://doi. org/10.1093/europace/euac237eng
dcterms.referencesWelton NJ, McAleenan A, Thom HH, Davies P, Hollingworth W, Higgins JP, et al. Screening strategies for atrial fibrillation: A systematic review and cost-effectiveness analysis. Health Technol Assess. 2017;21(29):1–236. DOI: https://doi.org/10.3310/hta21290eng
dcterms.references2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109–279. DOI: https://doi.org/10.1016/j. jacc.2023.08.017eng
dcterms.referencesFreedman B, Hindricks G, Banerjee A, Baranchuk A, Ching CK, Du X, et al. World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Glob Heart. 2021;16(1):41. DOI: https://doi. org/10.5334/gh.1023eng
dcterms.referencesNiiranen T, Schnabel R, Schutte AE, Biton Y, Boriani G, Buckley C, et al. Hypertension and atrial fibrillation: A frontier Review from the AF-SCREEN International Collaboration. Circulation. 2025;151(12): 863–877. DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.071047eng
dcterms.referencesNeal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021;385(12):1067–1077. DOI: https://doi.org/10.1056/ NEJMoa2105675eng
dcterms.referencesAminde LN, Nugraheni WP, Mubasyiroh R, Rachmawati T, Dwirahmadi F, Martini S, et al. Cost effectiveness analysis of low-sodium potassium-rich salt substitutes in Indonesia: An equity modelling study. Lancet Reg Health Southeast Asia. 2024;26:100432. DOI: https://doi.org/10.1016/j. lansea.2024.100432eng
dcterms.referencesMarklund M, Singh G, Greer R, Cudhea F, Matsushita K, Micha R, et al. Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: Modelling study. BMJ. 2020;369:m824. DOI: https://doi.org/10.1136/bmj.m824eng
dcterms.referencesBernabe-Ortiz A, Sal Y, Rosas VG, Ponce-Lucero V, Cárdenas MK, Carrillo-Larco RM, Diez-Canseco F, et al. Effect of salt substitution on community-wide blood pressure and hypertension incidence. Nat Med. 2020;26(3):374–378. DOI: https://doi.org/10.1038/s41591-020-0754-2eng
dcterms.referencesYuan Y, Jin A, Neal B, Feng X, Qiao Q, Wang H, et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: A cluster-randomized trial. Nat Med. 2023;29(4):973–981. DOI: https://doi.org/10.1038/s41591-023-02286-8eng
dcterms.referencesArsenijevic J, Groot W. Physical activity on prescription schemes (PARS): Do programme characteristics influence effectiveness? Results of a systematic review and meta-analyses. BMJ Open. 2017;7(2):e012156. DOI: https://doi.org/10.1136/bmjopen-2016-012156eng
dcterms.referencesPatterson R, McNamara E, Tainio M, de Sá TH, Smith AD, Sharp SJ, et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: A systematic review and dose response meta-analysis. Eur J Epidemiol. 2018;33(9):811–829. DOI: https://doi. org/10.1007/s10654-018-0380-1eng
dcterms.references2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. DOI: https://doi.org/10.1093/eurheartj/ ehw106eng
dcterms.references2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646. DOI: https://doi.org/10.1161/CIR.0000000000000678eng
dcterms.referencesSkotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris S, et al. Crdiovascular effects of electronic cigarettes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2019;26(11):1219–1228. DOI: https://doi.org/10.1177/2047487319832975eng
dcterms.referencesJeffers AM, Glantz S, Byers AL, Keyhani S. Association of cannabis use with cardiovascular outcomes among US adults. J Am Heart Assoc. 2024;13(5):e030178. Epub 2024 Feb 28. PMID: 38415581; PMCID: PMC10944074. DOI: https://doi.org/10.1161/JAHA.123.030178eng
dcterms.referencesRodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination compared with placebo for initial treatment of hypertension. J Am Coll Cardiol. 2024;84(24):2393–2403. DOI: https://doi.org/10.1016/j. jacc.2024.08.025eng
dcterms.references2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–e115. DOI: https://doi.org/10.1161/HYP.0000000000000065. Epub 2017 Nov 13. Erratum in: Hypertension. 2018 Jun;71(6):e140–e144. DOI: https://doi.org/10.1161/ HYP.0000000000000076eng
dcterms.references2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1–15. DOI: https://doi.org/10.1016/j.ejim.2024.05.033eng
dcterms.references2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. DOI: https://doi.org/10.1093/eurheartj/ehae178eng
dcterms.referencesWHO Model List of Essential Medicines – 23rd list, 2023. WHO/MHP/HPS/EML/2023.02. [Internet]. Available at: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02eng
dcterms.referencesO’Hagan E, McIntyre D, Nguyen T, Tan KM, Hanlon P, Siddiqui M, et al. A cross-sectional survey of fixed-dose combination antihypertensive medicine prescribing in twenty-four countries, including qualitative insights. Glob Heart. 2024;19(1):73. DOI: https://doi.org/10.5334/gh.1353eng
dcterms.referencesSouza KM, Giron N, Vallini J, Hallar K, Ordunez P, Rosende A, et al. Barriers to access to antihypertensive medicines: insights from the HEARTS initiative in Latin American and Caribbean region. J Pharm Policy Pract. 2024;17(1):2379045. DOI: https://doi.org/10.1080/20523211.2024.2379 045eng
dcterms.referencesMcGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta analysis. JAMA Cardiol. 2021;6(2):148–158. DOI: https://doi.org/10.1001/jamacardio.2020eng
dcterms.referencesAHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–3209. DOI: https://doi.org/10.1016/j.jacc.2018.11.002. Erratum in: J Am Coll Cardiol. 2019;73(24):3234–3237.eng
dcterms.referencesPAHO Strategic Fund Product List. Aug. 2023. Available at: https://www.paho.org/sites/default/files/ strategic-fund-product-list-230821_0.pdfeng
dcterms.referencesLasserson DS, Buclin T, Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart. 2011;97(21):1771–1775. DOI: https://doi.org/10.1136/hrt.2010.221473eng
dcterms.referencesBoima V, Doku A, Agyekum F, Tuglo LS, Agyemang C. Effectiveness of digital health interventions on blood pressure control, lifestyle behaviours and adherence to medication in patients with hypertension in low-income and middle-income countries: A systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2024;69:102432. DOI: https://doi.org/10.1016/j. eclinm.2024.102432eng
dcterms.referencesHe J, Ouyang N, Guo X, Sun G, Li Z, Mu J, et al. Effectiveness of a non-physician community health care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): An open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023;401(10380):928– 938. DOI: https://doi.org/10.1016/S0140-6736(22)02603-4eng
dcterms.referencesGiraldo GP, Joseph KT, Angell SY, Campbell NRC, Connell K, DiPette DJ, et al. Mapping stages, barriers and facilitators to the implementation of HEARTS in the Americas initiative in 12 countries: A qualitative study. J Clin Hypertens (Greenwich). 2021;23(4):755–765. DOI: https://doi.org/10.1111/ jch.14157eng
dcterms.referencesSchwalm JD, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, et al. A community based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): A cluster-randomised controlled trial. Lancet. 2019;394(10205):1231–1242. DOI: https://doi. org/10.1016/S0140-6736(19)31949-Xeng
dcterms.referencesGarcía-Zamora S, Pulido L. Vaccines in cardiology, an underutilized strategy to reduce the residual cardiovascular risk. Arch Peru Cardiol Cir Cardiovasc. 2024;5(1):29–39. DOI: https://doi.org/10.47487/ apcyccv.v5i1.349eng
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
PDF.pdf
Tamaño:
2.66 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca